Segmentation, Major Trends, and Competitive Overview of the Gene Therapy Market for Parkinson's Disease

The gene therapy sector for Parkinson's disease is poised for significant expansion as advancements in medical science and technology continue to drive innovation. With increasing investments and evolving treatment methods, this market is set to transform the therapeutic landscape for Parkinson's patients. Below, we explore the market's expected growth, influential companies, emerging trends, and key segments shaping its future.

Forecasted Market Size and Growth Trajectory of the Gene Therapy for Parkinson's Disease Market
The gene therapy market targeting Parkinson's disease is anticipated to experience remarkable growth, reaching a valuation of $2.05 billion by 2030. This surge corresponds to a robust compound annual growth rate (CAGR) of 26.0%. The expansion is fueled by heightened investments in treatments for neurodegenerative disorders, rising uptake of personalized gene therapies, and the progression of late-stage clinical trials. Additionally, demand for treatment options that modify disease progression and advancements in minimally invasive delivery technologies are contributing significantly. Key trends expected to influence the market include the increasing development of viral vector-based treatments, a stronger focus on strategies for dopamine restoration, growing application of neurotrophic factor gene delivery, refinement of precision intracerebral delivery methods, and greater attention to ensuring long-term therapeutic effectiveness.

Download a free sample of the gene therapy for parkinson's disease market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Prominent Companies Leading the Gene Therapy for Parkinson's Disease Market
Several notable firms play key roles in this market, including Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., and Tetraneuron S.L. A significant development occurred in January 2025 when BlackfinBio Limited, a UK-based clinical-stage gene therapy provider focused on rare neurological and dopamine-deficiency disorders, acquired the Parkinson's patent portfolio from Oxford Biomedica plc. This strategic move aims to accelerate BlackfinBio's BFB-201 program by leveraging Oxford Biomedica's intellectual property and expertise in gene and cell therapy technologies.

Critical Trends Driving Innovation in Gene Therapy for Parkinson's Disease
Industry players are increasingly concentrating on refining gene therapies to provide more accurate and effective treatments. One area of focus is regenerative medicine advanced therapy (RMAT), a special designation by the United States Food and Drug Administration (FDA) granted to regenerative products like cell and gene therapies intended to treat or modify serious diseases. In February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US gene therapy company, unveiled AB-1005, an investigational AAV2-GDNF gene therapy that received the FDA's RMAT designation. This status is designed to speed up the development and regulatory review of promising treatments. The designation was awarded based on clinical data from AskBio's Phase Ib open-label trial showing AB-1005's potential to slow disease progression and enhance motor function in Parkinson's patients.

View the full gene therapy for parkinson's disease market report:
https://www.thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Segment Breakdown and Market Share Outlook in Gene Therapy for Parkinson's Disease
This report segments the gene therapy market for Parkinson's disease into several categories, including:
1) Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy
2) Vector Type: Viral Vectors, Non-Viral Vectors
3) Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, and other target genes
4) Delivery Method: Intracerebral, Intravenous, and other delivery methods
5) End-User: Hospitals, Specialty Clinics, Research Institutes, and other end-user segments

Further subcategories refine these segments, such as distinguishing between viral and non-viral vectors within in vivo gene therapy, and between autologous and allogeneic cell-based therapies in ex vivo gene therapy.

Overall, the gene therapy market for Parkinson's disease is positioned for substantial growth, driven by innovative therapies, strategic partnerships, and evolving regulatory pathways that support accelerated development and commercialization.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.